Player FM 앱으로 오프라인으로 전환하세요!
Personalizing care in thyroid cancer using molecular tumor boards
Manage episode 342696733 series 3304844
In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.
References
- Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
JCO Precis Oncol 2021;5:PO.20.00495 - Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular
cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380 - Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
- VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
- Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
- Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
- Discuss “precision medicine” and new technologies, including “liquid biopsy”
- Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the second and third objective.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosure:
Dr. David Tamborero has no relevant disclosures to announce
32 에피소드
Manage episode 342696733 series 3304844
In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.
References
- Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
JCO Precis Oncol 2021;5:PO.20.00495 - Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular
cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380 - Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
- VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
- Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
- Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
- Discuss “precision medicine” and new technologies, including “liquid biopsy”
- Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the second and third objective.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosure:
Dr. David Tamborero has no relevant disclosures to announce
32 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.